Pharmacodynamic study of the oral hedgehog pathway inhibitor, vismodegib, in patients with metastatic castration-resistant prostate cancerBenjamin L. Maughan, Emmanuel S. Antonarakis, Brandon Luber et al.|Cancer Chemotherapy and Pharmacology|2016Cited by 31
Combining the pan‐aurora kinase inhibitor <scp>AMG</scp> 900 with histone deacetylase inhibitors enhances antitumor activity in prostate cancerChanning J. Paller, Sushant K. Kachhap|Cancer Medicine|2014Cited by 30